Bepirovirsen (Hibsago) Market to Reach USD 1,986.5 Million by 2035 at 29.0% CAGR as First Hepatitis B Functional Cure Launches

Pune, India, November 10, 2026 — The global Bepirovirsen (Hibsago) Market is estimated at USD 35.2 million in 2026, its launch year, and is projected to reach USD 1,986.5 million by 2035, growing at a CAGR of 29.0% from 2027 to 2035, according to the new Bepirovirsen Market report from Ameco Research. Sales are expected to reach USD 258.4 million in 2027, the first full year on the market. GSK's Hibsago was approved in Japan in August 2026 and by the U.S. FDA in October 2026, creating the first commercial market for a finite, cure-oriented chronic hepatitis B (CHB) treatment.

Bepirovirsen (also known as GSK3228836) is an antisense oligonucleotide discovered by Ionis Pharmaceuticals and developed and sold by GSK. It targets all hepatitis B virus RNAs, lowering viral proteins including hepatitis B surface antigen (HBsAg) and helping the immune system regain control of the virus. It is the first antisense therapy approved for CHB in the U.S. The 180-page study covers market size, clinical evidence, regulatory status, patient pool, segments, regional launches, and the competitive landscape for functional cure therapies.

Bepirovirsen Market Size and Forecast

Current nucleos(t)ide analogue (NA) drugs suppress the virus but rarely clear HBsAg, so most patients stay on them for life. Bepirovirsen is added to NA therapy for a fixed six-month course with the goal of functional cure: lasting HBsAg loss and undetectable HBV DNA after all treatment stops. Ameco Research expects revenue to climb steeply as approvals expand to the European Union, China, and other markets:

Key Takeaways

• Market size: USD 35.2 million in 2026, USD 258.4 million in 2027, and USD 1,986.5 million by 2035
• Growth rate: 29.0% CAGR from 2027 to 2035
• Leading region: North America, with about 72.9% of 2027 revenue
• Fastest-growing region: Europe, at a 50.7% CAGR after EU approval
• Largest HBsAg segment: Patients with baseline HBsAg above 100 to 1,000 IU/mL, at 38.9% in 2027
• Leading end user: Hospital hepatology and gastroenterology centers, with 57.1%
• Leading channel: Specialty pharmacies, at 47.3% in 2027, rising to 51.6% by 2035

What Do the Clinical Data Show?

Approvals are based on the global Phase III B-Well 1 and B-Well 2 trials in patients on stable NA therapy, both of which met their primary endpoint. Functional cure rates with standard NA therapy are typically below 1% after one year.

The U.S. label covers adults with CHB without cirrhosis who have been on NA therapy for at least six months, have suppressed HBV DNA, and have HBsAg of 3,000 IU/mL or lower, measured with an FDA-authorized quantitative test. This links Hibsago uptake directly to quantitative HBsAg testing.

Regulatory Status and Patient Pool

Japan granted the first global approval in August 2026, followed by U.S. FDA approval on October 20, 2026. The drug is under review by the European Medicines Agency and by China's NMPA, where it holds Breakthrough Therapy and Priority Review status. More than 240 million people live with chronic hepatitis B worldwide, including about 1.7 million in the U.S., and hepatitis B causes about 1.1 million deaths a year. Patients with HBsAg of 1,000 IU/mL or lower, who respond best, make up about 45% of diagnosed cases globally, and CHB accounts for more than half of liver cancer cases worldwide.

Key Growth Drivers

• Large unmet need: Current NA drugs rarely achieve HBsAg loss, leaving hundreds of millions of people on lifelong therapy.
• First-in-class functional cure: Bepirovirsen is the only approved therapy with Phase III proof of functional cure in CHB.
• Finite treatment: A six-month course could reduce long-term drug, monitoring, and liver cancer costs.
• Regulatory momentum: Breakthrough Therapy, Priority Review, and Japan's SENKU designation speed access.
• Strong commercial partners: GSK's global reach and Chia Tai Tianqing's footprint in China support uptake.

Market Trends in 2026

• From lifelong suppression to finite therapy: Treatment goals are shifting toward stopping therapy, and guidelines, payers, and specialists are adapting.
• HBsAg testing becomes the gateway: Because eligibility and response depend on baseline HBsAg, quantitative testing is set to become routine in CHB care.
• Country-by-country launches: In May 2026, GSK partnered with Sino Biopharmaceutical's Chia Tai Tianqing, which covers more than 5,000 medical centers, to prepare the China launch.
• Self-administration: After the first dose, patients may self-inject at home, moving much of the course out of the hospital.
• Combination regimens: Developers are testing bepirovirsen with siRNAs and immune modulators to raise cure rates and reach patients with higher HBsAg.

Challenges

Most treated patients do not achieve functional cure, and response falls as baseline HBsAg rises. The label excludes patients with cirrhosis, those not on NA therapy, and those with HBsAg above 3,000 IU/mL. Many people with CHB are undiagnosed, quantitative HBsAg testing is not yet routine, liver enzyme flares require regular blood tests during treatment, and a premium price must be justified to payers in cost-sensitive, high-prevalence markets.

Segment Analysis

By Baseline HBsAg Level

By HBeAg Status, End User, and Channel

HBeAg-negative patients accounted for 83.2% of revenue in 2027, while HBeAg-positive patients (16.8%) are growing faster at about a 30.7% CAGR. Hospital hepatology and gastroenterology centers held 57.1%, specialty clinics 30.2%, and community health centers 12.7%, the fastest-growing end user at about a 35.1% CAGR. Specialty pharmacies led distribution with 47.3%, hospital pharmacies held 38.4%, and retail and online pharmacies (14.3%) are growing fastest as self-injection spreads.

Regional Outlook

North America is expected to generate about USD 188.4 million in 2027, supported by FDA approval, high specialty drug prices, and established specialty pharmacy networks. Its share falls to about 46.9% by 2035 as launches in Europe and China ramp up; China, home to the world's largest CHB population, is the largest long-term opportunity once the drug is approved and reimbursed.

Competitive Landscape

GSK holds global rights to bepirovirsen and is its only marketer, with Ionis eligible for milestones and royalties. In China, Chia Tai Tianqing will buy the drug from GSK under an initial 5.5-year supply agreement and handle distribution and hospital access. Future competition will come from other functional cure approaches, including siRNAs, capsid assembly modulators, therapeutic vaccines, and TLR agonists such as Gilead's selgantolimod. Companies profiled include GSK plc, Ionis Pharmaceuticals, Sino Biopharmaceutical (Chia Tai Tianqing), Gilead Sciences, Aligos Therapeutics, Arbutus Biopharma, Arrowhead Pharmaceuticals, and Vir Biotechnology.

For questions on forecasts, pricing assumptions, or methodology, Make an Inquiry.

Opportunities

• EU and China approvals: These would greatly expand the eligible population.
• Broader HBsAg screening: Programs that identify suitable patients earlier.
• Combination regimens: Extending benefit to HBeAg-positive and higher-HBsAg patients.
• Functional cure care pathways: Biomarker monitoring after treatment ends.
• Emerging markets: Asia Pacific, Latin America, and Africa, where CHB burden is highest.

Related Ameco Research coverage includes the Hepatitis B Vaccine Market report, the Precision Medicine Market analysis, the AI in Drug Discovery Market report, and the Biotechnology Market study.

Report Scope

Who Should Read This Report?

• Pharmaceutical and biotech companies developing hepatitis B and RNA-targeted therapies.
• Investors and analysts modeling GSK, Ionis, and the functional cure pipeline.
• Specialty pharmacies and distributors planning launch logistics and patient support.
• Diagnostics companies sizing demand for quantitative HBsAg testing.
• Payers, health systems, and policymakers evaluating the value of finite, curative therapy.

The report supports investment planning with launch-curve forecasts to 2035, business strategy with patient segment analysis, market entry with country-level launch timing, and competitive intelligence on the functional cure pipeline. Buy the Bepirovirsen Market Report for immediate access.

Conclusion

Bepirovirsen opens a new chapter in hepatitis B care: the shift from lifelong suppression to a finite course aimed at functional cure. With sales forecast to rise from USD 258.4 million in 2027 to USD 1,986.5 million by 2035 at a 29.0% CAGR, uptake will depend on HBsAg testing, EU and China approvals, and payer acceptance. Ameco Research's report gives stakeholders the data to plan for this launch.

Explore the Bepirovirsen Market Report

Preview the data and methodology, ask about pricing and coverage, get the complete study, or request extra segments, country-level data, and research beyond the report’s scope.

About Ameco Research

Ameco Research is a market research and consulting firm that provides syndicated reports, customized research, and data-driven insight across industries including pharmaceuticals and healthcare, ICT, energy, automotive, and chemicals. Its analysts help businesses, investors, and institutions find growth opportunities and make informed strategic decisions.

Contact Us

Ameco Research
201, Vaidehi-Saaket, Baner - Pashan Link Rd, Pashan, Pune, Maharashtra 411021, India
Phone: +91 898 322 5533
E-mail: [email protected]
Website: www.amecoresearch.com